LLY

917.01

+0.29%↑

JNJ

238.27

+0.34%↑

ABBV

206.09

-1.3%↓

NVS

147.74

-2.09%↓

AZN

187.82

-0.93%↓

LLY

917.01

+0.29%↑

JNJ

238.27

+0.34%↑

ABBV

206.09

-1.3%↓

NVS

147.74

-2.09%↓

AZN

187.82

-0.93%↓

LLY

917.01

+0.29%↑

JNJ

238.27

+0.34%↑

ABBV

206.09

-1.3%↓

NVS

147.74

-2.09%↓

AZN

187.82

-0.93%↓

LLY

917.01

+0.29%↑

JNJ

238.27

+0.34%↑

ABBV

206.09

-1.3%↓

NVS

147.74

-2.09%↓

AZN

187.82

-0.93%↓

LLY

917.01

+0.29%↑

JNJ

238.27

+0.34%↑

ABBV

206.09

-1.3%↓

NVS

147.74

-2.09%↓

AZN

187.82

-0.93%↓

Search

United Therapeutics Corp

Open

SectorHealthcare

524.63 -0.87

Overview

Share price change

24h

Current

Min

521.36

Max

533.12

Key metrics

By Trading Economics

Income

26M

364M

Sales

-9.3M

790M

P/E

Sector Avg

19.192

57.833

Profit margin

46.102

Employees

1,400

EBITDA

61M

524M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+2.95% upside

Dividends

By Dow Jones

Next Earnings

29 kwi 2026

Market Stats

By TradingEconomics

Market Cap

2B

23B

Previous open

525.5

Previous close

524.63

News Sentiment

By Acuity

50%

50%

171 / 351 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Weak Bullish Evidence

United Therapeutics Corp Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

18 mar 2026, 22:51 UTC

Earnings

AIA Group Value of New Business Rose in 2025, Plans $1.7 Billion New Share Buyback

18 mar 2026, 21:40 UTC

Acquisitions, Mergers, Takeovers

Constellation Energy to Sell Portfolio of Assets for $5 Billion to Satisfy Regulators

18 mar 2026, 20:31 UTC

Earnings

Micron 2Q Sales Nearly Triple Amid Tight Memory Supply

18 mar 2026, 23:49 UTC

Market Talk
Major News Events

Nikkei May Fall on Renewed Concerns About Higher Energy Prices -- Market Talk

18 mar 2026, 23:31 UTC

Market Talk

Gold Rises on Likely Technical Recovery -- Market Talk

18 mar 2026, 22:49 UTC

Market Talk

New Zealand's Economic Recovery Has Yet to Find Footing -- Market Talk

18 mar 2026, 22:41 UTC

Market Talk

Woodside Energy Opts for 'Safe, Experienced' Choice as CEO -- Market Talk

18 mar 2026, 22:36 UTC

Earnings

AIA Group Value of New Business Rose in 2025, Plans $1.7B New Share Buyback

18 mar 2026, 22:24 UTC

Earnings

AIA Group Announces New Share Buyback of $1.7B >1299.HK

18 mar 2026, 22:23 UTC

Earnings

AIA Group 2025 Value of New Business Margin Was 58.5%, Up 3.6 Ppt on Year >1299.HK

18 mar 2026, 22:23 UTC

Earnings

AIA Group 2025 Value of New Business $5.52B Vs. $4.71B >1299.HK

18 mar 2026, 21:58 UTC

Earnings

Micron Sales Nearly Triple Amid Tight Memory Supply -- Update

18 mar 2026, 21:55 UTC

Market Talk
Earnings

Global Equities Roundup: Market Talk

18 mar 2026, 21:55 UTC

Market Talk
Earnings

Micron's Phone, PC Business Could Shrink Due to Memory Shortage -- Market Talk

18 mar 2026, 21:40 UTC

Market Talk

Fuel Price Rise Equates to 20 Bps Rate Hike on Australian Households -- Market Talk

18 mar 2026, 21:16 UTC

Market Talk

More Procter & Gamble Alumni Join Strobel at Coty -- Market Talk

18 mar 2026, 21:00 UTC

Major News Events

Iran War Puts Pressure on Japan's Economy. Takaichi Is In a Bind. -- Barrons.com

18 mar 2026, 20:58 UTC

Earnings

Micron 2Q Gross Margin Nearly Doubled Due to Higher Pricing, CFO Says

18 mar 2026, 20:41 UTC

Earnings

Micron Reports Extraordinary Earnings. Its Growth Is Accelerating. -- Barrons.com

18 mar 2026, 20:29 UTC

Earnings

Micron Reports Extraordinary Earnings. Its Growth Is Accelerating. -- Barrons.com

18 mar 2026, 20:25 UTC

Earnings

Micron Reports Extraordinary Earnings. Its Growth Is Accelerating. -- Barrons.com

18 mar 2026, 20:17 UTC

Earnings

These Stocks Are Today's Movers: Micron, Swarmer, Lumentum, Trade Desk, Macy's, Williams-Sonoma, and More -- Barrons.com

18 mar 2026, 20:14 UTC

Market Talk

Airlines Can't Offset Higher Fuel Prices for Long -- Market Talk

18 mar 2026, 20:09 UTC

Earnings

Micron Reports Extraordinary Earnings. The Stock Is Up. -- Barrons.com

18 mar 2026, 20:07 UTC

Earnings

Micron Technology Raises Qtr Dividend to 15c Vs. 11.5c >MU

18 mar 2026, 20:06 UTC

Earnings

Micron Technology Board Has Approved 30% Increase in Qtrly Div >MU

18 mar 2026, 20:04 UTC

Earnings

Micron Technology 2Q Operating Cash Flow $11.9 B >MU

18 mar 2026, 20:04 UTC

Earnings

Micron Technology Sees 3Q Operating Expenses About $1.6 B >MU

18 mar 2026, 20:04 UTC

Earnings

Micron Technology Sees 3Q Gross Margin About 81% >MU

18 mar 2026, 20:03 UTC

Earnings

Micron Technology Sees 3Q Adj EPS $19.15 +/- 40c >MU

Peer Comparison

Price change

United Therapeutics Corp Forecast

Price Target

By TipRanks

2.95% upside

12 Months Forecast

Average 546 USD  2.95%

High 705 USD

Low 35 USD

Based on 13 Wall Street analysts offering 12 month price targets forUnited Therapeutics Corp - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

13 ratings

9

Buy

4

Hold

0

Sell

Technical Score

By Trading Central

292.345 / 309.245Support & Resistance

Short Term

Weak Bullish Evidence

Intermediate Term

Weak Bullish Evidence

Long Term

Bearish Evidence

Sentiment

By Acuity

171 / 351 Ranking in Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About United Therapeutics Corp

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
help-icon Live chat